Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration.

Histologically, mice treated with locally delivered BPs experience a decrease in the tumor burden (12±7.7%), compared the control group (23±20%), however the difference did not reach statistical significance ( P = 0.34).

also in 111,027 other papers

Despite using a relatively high dose of zoledronate (2 μg) directly at the site of bone tumor one week after cancer cell implantation, our results showed a trend that tumor growth was less in the treatment versus control groups.

also in 53,322 other papers